Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19521299 | 0.84 | LMNA (0.45) | BRD4CREBBPS1PR1RET | |
| SCHEMBL19521380 | 0.84 | MELK (0.38) | CREBBP | |
| SCHEMBL19521374 | 0.84 | TNKS2 (0.36) | CREBBP | |
| SCHEMBL19521364 | 0.83 | PGR (0.39) | BRD4CREBBP | |
| SCHEMBL19542077 | 0.82 | BRD4 (0.37) | BRD4CREBBPS1PR1RET | |
| SCHEMBL19521350 | 0.82 | GLA (0.38) | CREBBP | |
| SCHEMBL19521325 | 0.80 | MELK (0.40) | CREBBPPRMT5WDR77 | |
| SCHEMBL19541753 | 0.79 | BRPF1 (0.39) | BRD4CREBBPRET | |
| SCHEMBL19521300 | 0.76 | NOS3 (0.35) | BRD4CREBBP | |
| SCHEMBL21071834 | 0.73 | AXL (0.47) | BRD4CREBBPRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230119547-A1 | DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES | FGH BIOTECH INC (US) | 2023-04-20 | — | — | US | claimed |
| US-20230119547-A1 | DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES | FGH BIOTECH INC (US) | 2023-04-20 | — | — | US | disclosed |
| US-11497738-B2 | Di-substituted pyrazole compounds for the treatment of diseases | FGH BIOTECH, INC. (US) | 2022-11-15 | — | — | US | disclosed |
| EP-3448851-B1 | DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES | FGH BIOTECH INC (US) | 2022-03-23 | — | — | EP | disclosed |
| CN-109476635-B | Disubstituted pyrazoles for treatment of diseases | FGH生物科技公司 | 2021-07-13 | — | — | CN | disclosed |
| US-20190134017-A1 | DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-05-09 | — | — | US | disclosed |
| WO-2017190086-A1 | DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES | FGH BIOTECH, INC. (US) | 2017-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190134017-A1 | DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES | SREBF1, SREBF2, CYP27A1 | BRD4 322/4885CREBBP 136/4885S1PR1 1107/4885 |
| US-20230119547-A1 | DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES | SREBF1, SREBF2, CYP27A1 | BRD4 322/4885CREBBP 136/4885S1PR1 1107/4885 |
| US-11497738-B2 | Di-substituted pyrazole compounds for the treatment of diseases | SREBF1, SREBF2, CYP27A1 | BRD4 322/4885CREBBP 136/4885S1PR1 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.